Key Resolutions

1. Special Resolution: Reappointment of Mrs. Sudeepthi Gopineedi as Whole-Time Director

  • Purpose: Reappointment for a further period of 5 years commencing from September 2, 2026
  • Current Tenure: Ends on September 1, 2026 (originally appointed on September 2, 2021)
  • Board Approval Date: May 29, 2026
  • Remuneration: Monthly remuneration in the range of ₹2.50 lakh to ₹4.00 lakh
  • Additional Benefits: Perquisites, commission on profits, annual bonus, gratuity, leave encashment
  • Qualifications: Postgraduate from BITS-Pilani in Chemistry, Bachelor's in Computer Science Engineering
  • Experience: Previously worked with Amazon, Oracle, The World Bank, and Blue Cross Blue Shield Association
  • Current Shareholding: 199,494 shares (6.60%)
  • FY 2025-26 Remuneration: ₹26,76,947 (Salary: ₹24,00,000 + Perks: ₹2,76,947)
  • Relationship: Daughter of Mr. TVVSN Murthy (Managing Director) and sibling of Mr. TV Praveen (Executive Director)

2. Special Resolution: Managerial Remuneration to Executive Directors

  • Purpose: Approval for aggregate managerial remuneration exceeding 5% of net profits
  • Maximum Annual Limits:
  • Mr. TVVSN Murthy: ₹1,98,00,000
  • Mr. TV Praveen: ₹1,08,00,000
  • Mrs. Sudeepthi Gopineedi: ₹48,00,000
  • Total Maximum: ₹3,54,00,000 annually
  • No-profit Scenario Cap: ₹5,00,00,000 aggregate

3. Ordinary Resolution: Material Related Party Transactions for 2026-27

  • Materiality Threshold: 10% of annual consolidated turnover (₹33.37 crore based on FY 2025-26 turnover of ₹333.79 crore)
  • Proposed Transactions:
  • Mahi Drugs Private Limited (Subsidiary): ₹85.10 crore aggregate limit
  • Purchase of Goods: ₹40 crore
  • Sale of Goods: ₹10 crore
  • Purchase of Services: ₹5 crore
  • Sale of Services: ₹10 crore
  • Trade Advance Payable: ₹20 crore
  • Lease Rent Receipt: ₹0.10 crore
  • Purogene Labs Private Limited: ₹50.60 crore aggregate limit
  • Purchase of Goods: ₹10 crore
  • Sale of Goods: ₹10 crore
  • Purchase of Services: ₹20 crore
  • Sale of Services: ₹0.50 crore
  • Trade Advance Payable: ₹10 crore
  • Lease Rent Receipt: ₹0.10 crore
  • Nature: Ordinary course of business at arm's length basis
  • Board Approval Date: February 11, 2026

4. Ordinary Resolution: Material Related Party Transactions of Subsidiary for 2026-27

  • Related Party: ChemWerth Inc, USA (strategic investor holding 35% in Mahi Drugs)
  • Proposed Limit: ₹55.00 crore for sale/purchase of goods and services
  • Subsidiary Standalone Turnover: ₹59.02 crore (FY 2025-26)

Voting Details

  • Cut-off Date: July 24, 2026
  • Voting Period: July 30, 2026 (9:00 AM IST) to August 28, 2026 (5:00 PM IST)
  • Results Declaration: August 31, 2026
  • Scrutinizer: Mr. C. Sudhir Babu, Practicing Company Secretary (FCS No. 7666)
  • E-voting Provider: Central Depository Services (India) Limited (CDSL)
  • Resolution Effective Date: August 28, 2026 (if passed)

Company Background

  • Business: Manufacturing, research, development and commercialization of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates and bulk drugs
  • Contact: 40-6628 8888 | cs@haleoslabs.com

Financial Impact

  • Director remuneration commitments up to ₹3.54 crore annually
  • Related party transaction approvals up to ₹190.70 crore aggregate
  • All transactions subject to arm's length pricing and ordinary course of business